Emergency Medicine International / 2019 / Article / Tab 2

Research Article

Cognitive Impairment among Cardiac Arrest Survivors in the ICU: A Retrospective Study

Table 2

Patient characteristics according to first and last MMSE scores among participants with a follow-up MMSE (n = 53).

Initial MMSE scoreLast MMSE score
MMSE ≥ 24 (n = 12)MMSE < 24 (n = 41)MMSE ≥ 24 (n = 35)MMSE < 24 (n = 18)

Demographics
Male7 (58.3)29 (70.7)0.41823 (65.7)13 (72.2)0.631
Age, years42.6 ± 12.244.3 ± 13.90.69840.9 ± 12.649.7 ± 13.40.023
Comorbidities
CAD1 (8.3)4 (9.8)0.8824 (11.4)1 (5.6)0.488
CHF0 (0.0)1 (2.4)0.5851 (2.9)0 (0.0)0.469
Arrhythmia0 (0.0)3 (7.3)0.3351 (2.9)2 (11.1)0.218
Hypertension3 (25.0)5 (12.2)0.2765 (14.3)3 (16.7)0.819
Diabetes mellitus0 (0.0)1 (2.4)0.5851 (2.9)0 (0.0)0.469
Malignancy0 (0.0)1 (2.4)0.5851 (2.9)0 (0.0)0.469
OHCA10 (83.3)38 (92.7)0.33031 (88.6)17 (94.4)0.488
Cardiac cause10 (83.3)38 (92.7)0.33033 (94.3)15 (83.3)0.196
Shockable rhythm8 (66.7)31 (75.6)0.53728 (80.0)11 (61.1)0.140
Witnessed10 (83.3)32 (78.0)0.69129 (82.9)13 (72.2)0.366
Bystander CPR9 (75.0)23 (56.1)0.23923 (65.7)9 (50.0)0.268
Time to ROSC, min15.6 ± 8.320.6 ± 12.70.20716.1 ± 11.725.9 ± 9.90.004
Midazolam dose, mg236.3 (184.5–286.3)239.7 (170.9–344.4)0.774242.0 (190.7–342.8)208.6 (133.6–342.2)0.419
Time to obey, day3.0 (2.0–3.0)3.0 (3.0–3.0)0.1513.0 (3.0–3.0)3.0 (3.0–3.0)0.335
Time to exam, day3.5 (3.0–4.0)3.0 (3.0–4.0)0.9815.0 (5.0–7.0)7.0 (5.0–12.5)0.041
Time interval from last midazolam to exam, day1.0 (0.0–1.8)1.0 (0.0–1.0)0.9012.0 (2.0–4.0)5.0 (2.0–10.3)0.011
LOS, day11.5 (9.0–16.3)15.0 (9.5–21.0)0.13913.0 (9.0–17.0)16.0 (13.0–34.5)0.013

Median (interquartile range).

You are browsing a BETA version of Hindawi.com. Click here to switch back to the original design.